future of glp 1 Why GLP-1 drugs are changing the metabolic health Oral GLP-1-Based Therapeutics in the

Moderate fat is the sweet spot

S.HsiehJ.et al

A major contributor was prescription drug spending, which rose 9.4% in 2025, driven in part by growing use of GLP-1 medications, some of which have list prices exceeding $1,000 per month, according to various estimates

To address these questions, we conducted a longitudinal analysis of sequential blood samples obtained from C57BL/6 mice before and during pregnancy

With stratification by sex, the analyses yielded similar results, with a significantly higher IRR of liver (2.52), pancreatic (33.84), and prostate (2.95) cancers in men and a significantly higher IRR of gallbladder and biliary tract (12.19), pancreatic (13.49), and breast (2.16) cancers in women

The DPP-4 inhibitor vildagliptin impacts the gut microbiota and prevents disruption of intestinal homeostasis induced by a Western diet in mice